Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis.

Liyanarachchi S, Li W, Yan P, Bundschuh R, Brock P, Senter L, Ringel MD, de la Chapelle A, He H.

J Clin Endocrinol Metab. 2016 Nov;101(11):4005-4013. Epub 2016 Jul 26.

2.

The synergic effect of BRAFV600E mutation and multifocality on central lymph node metastasis in unilateral papillary thyroid carcinoma.

Qu HJ, Qu XY, Hu Z, Lin Y, Wang JR, Zheng CF, Tan Z.

Endocr J. 2018 Jan 30;65(1):113-120. doi: 10.1507/endocrj.EJ17-0110. Epub 2017 Oct 26.

3.
4.

[Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].

Shi CL, Guo Y, Lyu YC, Nanding ZABYS, Gao WC, Shi TF, Qin HD, Liu SY.

Zhonghua Zhong Liu Za Zhi. 2017 May 23;39(5):361-366. doi: 10.3760/cma.j.issn.0253-3766.2017.05.008. Chinese.

PMID:
28535653
5.

The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.

Daliri M, Abbaszadegan MR, Bahar MM, Arabi A, Yadollahi M, Ghafari A, Taghehchian N, Zakavi SR.

Endocr Res. 2014;39(4):189-93. doi: 10.3109/07435800.2013.879169. Epub 2014 Mar 28.

PMID:
24679337
6.

Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.

Shi C, Guo Y, Lv Y, Nanding A, Shi T, Qin H, He J.

PLoS One. 2016 Dec 9;11(12):e0167414. doi: 10.1371/journal.pone.0167414. eCollection 2016.

7.

Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.

Kim SK, Woo JW, Lee JH, Park I, Choe JH, Kim JH, Kim JS.

Surgery. 2015 Dec;158(6):1500-11. doi: 10.1016/j.surg.2015.05.016. Epub 2015 Jun 26.

PMID:
26120069
8.

Identification of Long Noncoding RNAs Deregulated in Papillary Thyroid Cancer and Correlated with BRAFV600E Mutation by Bioinformatics Integrative Analysis.

Goedert L, Plaça JR, Fuziwara CS, Machado MCR, Plaça DR, Almeida PP, Sanches TP, Santos JFD, Corveloni AC, Pereira IEG, de Castro MM, Kimura ET, Silva WA Jr, Espreafico EM.

Sci Rep. 2017 May 10;7(1):1662. doi: 10.1038/s41598-017-01957-0.

9.

Long noncoding RNA HIT000218960 promotes papillary thyroid cancer oncogenesis and tumor progression by upregulating the expression of high mobility group AT-hook 2 (HMGA2) gene.

Li T, Yang XD, Ye CX, Shen ZL, Yang Y, Wang B, Guo P, Gao ZD, Ye YJ, Jiang KW, Wang S.

Cell Cycle. 2017 Jan 17;16(2):224-231. doi: 10.1080/15384101.2016.1261768. Epub 2016 Dec 8.

10.

Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance.

Lan X, Sun W, Zhang P, He L, Dong W, Wang Z, Liu S, Zhang H.

Tumour Biol. 2016 May;37(5):6117-23. doi: 10.1007/s13277-015-4461-4. Epub 2015 Nov 26.

PMID:
26611646
11.

Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.

Lukas J, Drabek J, Dudesek B, Vazan P, Stranska J, Jancik S, Mackova M, Syrucek M, Lukas D, Duskova J, Dundr P, Hintnausova B, Jiskra J.

Exp Clin Endocrinol Diabetes. 2014 May;122(5):268-72. doi: 10.1055/s-0034-1372624. Epub 2014 May 16.

PMID:
24839220
12.

Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.

Gandolfi G, Sancisi V, Torricelli F, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A.

J Clin Endocrinol Metab. 2013 May;98(5):E934-42. doi: 10.1210/jc.2012-3930. Epub 2013 Mar 26.

PMID:
23533235
13.

Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.

Huang Y, Liao D, Pan L, Ye R, Li X, Wang S, Ye C, Chen L.

Eur J Endocrinol. 2013 Apr 15;168(5):675-81. doi: 10.1530/EJE-12-1029. Print 2013 May.

PMID:
23416953
14.

Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.

Bartolome A, Boskovic S, Paunovic I, Bozic V, Cvejic D.

APMIS. 2016 Apr;124(4):271-7. doi: 10.1111/apm.12505. Epub 2016 Jan 11.

PMID:
26750533
15.

BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.

Kurtulmus N, Duren M, Ince U, Cengiz Yakicier M, Peker O, Aydın O, Altiok E, Giray S, Azizlerli H.

Endocrine. 2012 Oct;42(2):404-10. Epub 2012 Mar 17.

PMID:
22426956
16.

BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.

Rossi ED, Martini M, Capodimonti S, Lombardi CP, Pontecorvi A, Vellone VG, Zannoni GF, Larocca LM, Fadda G.

Cancer Cytopathol. 2013 Jun;121(6):291-7. doi: 10.1002/cncy.21258. Epub 2012 Nov 28.

17.

BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.

Liao T, Qu N, Shi RL, Guo K, Ma B, Cao YM, Xiang J, Lu ZW, Zhu YX, Li DS, Ji QH.

Oncotarget. 2017 Jan 3;8(1):238-247. doi: 10.18632/oncotarget.10825.

18.

Upregulation of long noncoding RNA MALAT1 in papillary thyroid cancer and its diagnostic value.

Liu J, Dong H, Yang Y, Qian Y, Liu J, Li Z, Guan H, Chen Z, Li C, Zhang K, Zhang Q, Cao W, Lv J.

Future Oncol. 2018 Dec;14(29):3015-3022. doi: 10.2217/fon-2018-0416. Epub 2018 Jul 10.

PMID:
29987950
19.

A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.

Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I, Moccia T, Budillon A, Vitale M.

J Clin Endocrinol Metab. 2012 Jul;97(7):2333-40. doi: 10.1210/jc.2011-3106. Epub 2012 Apr 16.

PMID:
22508706
20.

Genome-wide analysis of long noncoding RNA expression profile in papillary thyroid carcinoma.

Lan X, Zhang H, Wang Z, Dong W, Sun W, Shao L, Zhang T, Zhang D.

Gene. 2015 Sep 10;569(1):109-17. doi: 10.1016/j.gene.2015.05.046. Epub 2015 May 21.

PMID:
26003293

Supplemental Content

Support Center